Myocardial phosphoproteomics and single cardiomyocyte force measurements endorse DYRK1A as a candidate therapeutic target for incomplete reverse remodelling after aortic valve replacement
Event: Heart Failure 2023
Topic: Cardiac Diseases
Session: ePosters in basic science 2
ESC 365 is supported by
